Skip to main content
Premium Trial:

Request an Annual Quote

Good Apart, Bad Together

Using a new computer algorithm they created that compiles reams of data on adverse drug reactions, Stanford University researchers have shown thousands of previously unknown side effects caused when some drugs are taken in combination, reports Nature News' Heidi Ledford. "Although clinical trials are often designed to assess the safety of a drug in addition to how well it works, the size of the trials needed to detect the full range of drug interactions would surpass even the large, late-stage clinical trials sometimes required for drug approval," Ledford says. So this algorithm, published in Science Translational Medicine is another way for doctors and regulators to assess a drug's safety profile as it's used in real time.

To reduce the bias inherent in adverse drug reaction reporting — for example, Ledford says, certain drugs are taken by certain segments of the population, which may be suffering from co-morbidities — the algorithm is designed to match data from each patient taking a drug to a control patient with the same condition. "The approach automatically corrected for several known sources of bias, including those linked to gender, age, and disease," Ledford says.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.